CO2021003805A2 - Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso - Google Patents

Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso

Info

Publication number
CO2021003805A2
CO2021003805A2 CONC2021/0003805A CO2021003805A CO2021003805A2 CO 2021003805 A2 CO2021003805 A2 CO 2021003805A2 CO 2021003805 A CO2021003805 A CO 2021003805A CO 2021003805 A2 CO2021003805 A2 CO 2021003805A2
Authority
CO
Colombia
Prior art keywords
pediatric
vitamin
methods
dosage forms
preparation
Prior art date
Application number
CONC2021/0003805A
Other languages
English (en)
Inventor
Praful Balavant Deshpande
Stephen James Quinlan
Marta Golec
John Gerard O'brien
James Joseph Mcdonald
Reem Elamein Elsiddig
Ken O'shea
Original Assignee
Opko Ireland Global Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Ireland Global Holdings Ltd filed Critical Opko Ireland Global Holdings Ltd
Publication of CO2021003805A2 publication Critical patent/CO2021003805A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen formas de dosificación pediátricas y de liberación modificada de compuestos de vitamina D, y métodos de elaboración y uso de las mismas.
CONC2021/0003805A 2018-08-31 2021-03-25 Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso CO2021003805A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862725940P 2018-08-31 2018-08-31
PCT/IB2019/057360 WO2020044314A1 (en) 2018-08-31 2019-08-30 Vitamin d pediatric dosage forms, methods of making and using

Publications (1)

Publication Number Publication Date
CO2021003805A2 true CO2021003805A2 (es) 2021-04-19

Family

ID=68165642

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0003805A CO2021003805A2 (es) 2018-08-31 2021-03-25 Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso

Country Status (21)

Country Link
US (3) US11000480B2 (es)
EP (1) EP3843706A1 (es)
JP (1) JP2021535155A (es)
KR (1) KR20210054539A (es)
CN (1) CN112912067A (es)
AU (3) AU2019329905B2 (es)
BR (1) BR112021003788A2 (es)
CA (1) CA3110020A1 (es)
CL (2) CL2021000493A1 (es)
CO (1) CO2021003805A2 (es)
CR (1) CR20210158A (es)
DE (1) DE202019005769U1 (es)
EA (1) EA202190633A1 (es)
EC (1) ECSP21021189A (es)
IL (1) IL280937A (es)
MX (1) MX2020011740A (es)
PE (1) PE20211489A1 (es)
PH (1) PH12021550413A1 (es)
SG (1) SG11202101905YA (es)
TW (1) TW202034905A (es)
WO (1) WO2020044314A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116033940A (zh) 2020-04-06 2023-04-28 艾尔金制药有限公司 激活内源性抗菌药物治疗sars-cov-2感染
AU2021285494A1 (en) 2020-05-31 2022-12-08 Eirgen Pharma Ltd. Hard capsule dosage form and uses thereof
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN114176164A (zh) * 2021-12-17 2022-03-15 广东驱动力生物科技股份有限公司 反刍动物用水溶性抗应激助剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59155309A (ja) * 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンｄ↓３類組成物
CA2065603C (en) * 1991-04-09 2007-04-03 Hiroki Itoh Stabilized vitamin d preparation
NZ254424A (en) * 1992-06-22 1997-09-22 Lunar Corp Pharmaceutical composition and use of 1 alpha hydroxy-pre-vitamin d
US7632518B2 (en) * 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
EP1993559B1 (en) * 2006-02-03 2016-06-22 OPKO Renal, LLC Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
WO2008134512A1 (en) * 2007-04-25 2008-11-06 Cytochroma Inc. Oral controlled release compositions comprising vitamin d compound and waxy carrier
CN101584683A (zh) * 2009-06-12 2009-11-25 沈阳药科大学 美托拉宗缓释胶囊及其制备方法
WO2012047098A1 (en) * 2010-10-04 2012-04-12 Dishman Pharmaceuticals And Chemicals Ltd. Encapsulated fat-soluble vitamin
WO2013105026A1 (en) * 2012-01-09 2013-07-18 Department Of Biotechnology (Dbt) A process for preparing solid lipid sustained release nanoparticles for delivery of vitamins
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US20160008377A1 (en) * 2014-07-12 2016-01-14 Aphios Corporation Formulations and compositions of vitamin d analogs for treating and preventing cancer and other diseases
WO2016020508A2 (en) * 2014-08-07 2016-02-11 Opko Ireland Global Holdings Ltd. Adjunctive therapy with 25-hydroxyvitamin d
CN108420797B (zh) * 2018-05-09 2022-05-03 南京海融制药有限公司 维生素d类似物制剂及其制备方法

Also Published As

Publication number Publication date
TW202034905A (zh) 2020-10-01
CR20210158A (es) 2021-05-21
US11000480B2 (en) 2021-05-11
PH12021550413A1 (en) 2021-09-27
CL2023002539A1 (es) 2024-02-23
CN112912067A (zh) 2021-06-04
ECSP21021189A (es) 2021-04-29
AU2019329905B2 (en) 2024-02-01
PE20211489A1 (es) 2021-08-11
SG11202101905YA (en) 2021-03-30
US20210401752A1 (en) 2021-12-30
CL2021000493A1 (es) 2021-07-23
US20200338006A1 (en) 2020-10-29
BR112021003788A2 (pt) 2021-06-08
EP3843706A1 (en) 2021-07-07
CA3110020A1 (en) 2020-03-05
EA202190633A1 (ru) 2021-07-12
AU2019329905A1 (en) 2021-03-18
KR20210054539A (ko) 2021-05-13
IL280937A (en) 2021-04-29
DE202019005769U1 (de) 2022-01-13
WO2020044314A1 (en) 2020-03-05
AU2021107168A4 (en) 2021-12-09
US20220000783A1 (en) 2022-01-06
MX2020011740A (es) 2021-04-19
AU2021107174A4 (en) 2021-12-09
JP2021535155A (ja) 2021-12-16

Similar Documents

Publication Publication Date Title
CO2018003477A2 (es) Anticuerpos anti-pd1 y métodos de uso
DOP2021000022A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
ECSP21021189A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
AR114687A1 (es) Pares citoquinas / receptores ortogonales biológicamente relevantes
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
CU20160187A7 (es) (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobencil)carbamoil)-2,3,4,5,7,9,13, 13a-octahidro-2,5-metanopirido[1',2':4,5]pirazino[2,1-b][1,3]oxazepin-8-olato de sodio
CO2017004714A2 (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
ECSP18049762A (es) Nuevos anticuerpos anti-claudina y sus métodos de uso
CL2017001661A1 (es) Compuestos biciclicos fusionados para el tratamiento de una enfermedad.
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
BR112019003987A2 (pt) formas sólidas de mesilato de cenicriviroc e processos de produção das formas sólidas de mesilato de cenicriviroc
CL2021003498A1 (es) Compuesto de pirazolona y pirimidina, y método de preparación y uso del mismo
CL2021000855A1 (es) Replicones basados en alfavirus para la administración de bioterapias.
AR119997A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
DOP2021000170A (es) Formulacion de anticuerpos terapeuticos
CO2017010692A2 (es) Construcciones de calicheamicina y sus métodos de uso
MX2020003730A (es) Nueva sal y formas en estado solido de escitalopram.
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
BR112018070603A2 (pt) formulações líquidas de fosfaplatina
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
CL2021002836A1 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos (divisional de la solicitud n° 201900424)
CO2021003295A2 (es) (r)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)bencil)piperazin-1-carboxilato cristalino, composiciones y sus métodos de uso